Nanometabolomics elucidated oral Mo₂C nanozyme-based therapy towards sleep deprivation-induced intestinal metabolic disorders via the regulation of ROS-related metabolism

Accumulation of excessive ROS in the intestine has been identified as a key factor contributing to body injury induced by sleep deprivation (SD), potentially leading to intestinal inflammation and even impacting lifespan. Our previous research has demonstrated that Mo₂C nanozyme, a transition metal carbide, exhibits remarkable bioactivity in the catalytic degradation of ROS by mimicking certain bioenzymes. This property presents a promising therapeutic approach for SD-induced intestinal injury. Moreover, the burgeoning field of nanometabolomics (nanomaterial-based integrated metabolomics) allows for intricate profiling of metabolic reprogramming at the molecular level following exposure to nanomaterials, offering valuable insights into the impact of Mo₂C nanozyme therapy on changes in intestinal metabolism. In this study, the therapeutic effects of Mo₂C nanozyme in a mouse model of SD using nanometabolomics techniques was investigated. The results suggest during SD, oral application of Mo₂C nanozyme can effectively eliminates intestinal ROS, restores homeostasis to metabolism-related biological processes and rehabilitated the probiotic diversity in the intestine. Notably, the therapeutic effect was more pronounced in the small intestine compared to the large intestine. This research contributes to the expanding biomedical applications of Mo₂C, providing valuable insights into its molecular mechanisms and supporting its potential future clinical use. © 2024 Elsevier Ltd